Poseida Therapeutics gets FDA orphan drug designation for P-BCMA-ALLO1 in multiple myeloma

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a trailblazer in the field of clinical-stage cell and gene therapy, has achieved a significant milestone with the U.S. Food ... Read More